Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.200
+0.020 (0.92%)
At close: Feb 27, 2026, 4:00 PM EST
2.191
-0.009 (-0.42%)
After-hours: Feb 27, 2026, 7:33 PM EST
Editas Medicine Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 4.50, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 104.55% from the current stock price of 2.20.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 5, 2025.
Analyst Ratings
The average analyst rating for Editas Medicine stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +127.27% | Sep 5, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $3 → $4 | Hold | Maintains | $3 → $4 | +81.82% | Sep 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $5 | Strong Buy | Maintains | $3 → $5 | +127.27% | Aug 15, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +172.73% | Aug 13, 2025 |
| Baird | Baird | Buy Maintains $8 → $4 | Buy | Maintains | $8 → $4 | +81.82% | May 13, 2025 |
Financial Forecast
Revenue This Year
21.41M
from 32.31M
Decreased by -33.73%
Revenue Next Year
14.40M
from 21.41M
Decreased by -32.74%
EPS This Year
-2.05
from -2.88
EPS Next Year
-1.16
from -2.05
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 32.3M | 31.5M | ||||
| Avg | 21.4M | 14.4M | ||||
| Low | 16.0M | 2.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.0% | 47.1% | ||||
| Avg | -33.7% | -32.7% | ||||
| Low | -50.6% | -90.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.95 | -0.65 | ||||
| Avg | -2.05 | -1.16 | ||||
| Low | -2.09 | -1.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.